1. Introduction {#s0005}
===============

Chagas disease is an anthropozoonosis from the Central and South American continent, caused by the protozoan flagellate *Trypanosoma cruzi* (*T. cruzi*) and considered a neglected parasitic illness which has spread from its original boundaries to historically non-endemic areas due to widespread migration \[[@bb0005],[@bb0010]\]. Around 6--7 million subjects are infected with *T. cruzi* worldwide. According to the Bulletin of the World Health Organization the increased frequency of *T. cruzi* infected people in the United States, Europe and the Western Pacific Region is evidenced \[[@bb0010]\]. Chagas disease has become an important threat being considered an extremely debilitating illness, normally linked to poverty, affecting populations with low visibility and exerts a considerable impact on morbidity and mortality with more than 10,000 deaths annually in Latin America \[[@bb0015]\] Chagas disease has increased incidence in immunocompromised people and elderly population \[[@bb0020]\].

It is well established that immune cells share receptors for hormones and cytokines through the action of systemic and local regulatory mechanisms. When one of these systems is disturbed by pathogen invasion, the physiological profile of these interactions changes, triggering the release of proinflammatory cytokines and hormones. The immuno-endocrine balance can deeply influence the experimental *T. cruzi* progression inside the host\'s body \[[@bb0025]\].

Some available data also reveal that a deregulation of the hypothalamic-pituitary-adrenal (HPA) axis during the acute *T. cruzi* infection induces an immunosuppression that is related to endocrine changes involving a circuit with regulatory properties in which cytokines and hormones produced by the HPA axis play essential role \[[@bb0030]\]. This immuno-endocrine cross-talk begins when HPA axis stimulation promotes the secretion of pituitary adrenocorticotropic hormone (ACTH) and adrenocortical glucocorticoids (GCs), triggered by the release pro-inflammatory cytokines like IL-6 or IL-1β into the circulation \[[@bb0035],[@bb0040]\]. Others data show that glucocorticoids drive changes in the mitochondrial biogenesis \[[@bb0045]\] interfering with the stress response. Although active glucocorticoids in the circulation are primarily derived from the adrenal gland as part of the HPA axis, they can also be produced from their inactive substrate 11-dehydrocorticosterone (11-DHC) by the enzyme 11β-HSD1 \[[@bb0050]\] as well in other sites such as thymus, brain and intestinal tract \[[@bb0055]\]. Additionally, elevated corticosterone levels contribute to the aging process and age-related diseases \[[@bb0060]\].

Melatonin (*N*-acetyl-5-methoxytryptamine) is a pleiotropic \[[@bb0065]\] signaling substance with vital role in adjusting the circadian rhythmicity \[[@bb0070],[@bb0075]\] and mitochondrial homeostasis \[[@bb0080]\]. The finding of melatonin synthesis in mitochondria \[[@bb0080]\] where it likely functions as an effective antioxidant \[[@bb0065],[@bb0080],[@bb0085]\], anti-apoptotic \[[@bb0090]\], anti-aging \[[@bb0095]\], oncostatic \[[@bb0100]\], immunomodulatory \[[@bb0105], [@bb0110], [@bb0115]\], free radical scavenger \[[@bb0120]\] and anti-inflammatory, demonstrate that the melatonergic pathways are present in different species and types of cell, such as immune cells out of pinealocytes \[[@bb0125], [@bb0130], [@bb0135]\]. Confirming this relationship, the presence of MT1 and MT2 melatonin receptors and its necessary biosynthetic machinery for producing this indoleamine in mitochondria has been described \[[@bb0125]\].

Several works have shown that besides the coordination of several different genes and hormones, melatonin is the main hormone in the regulation of our sleep-wake cycles. Although many conflicting results have been yielded, advanced age is related increased oxidative stress, respiratory functional decline, susceptibility to apoptosis \[[@bb0140]\] as well as a worse prognosis during the late phase of Chagas disease \[[@bb0145]\]. As long as age travels, a decay in pineal melatonin concentrations happens \[[@bb0150]\], triggering alterations in mitochondrial dynamics and immune cells phenotype \[[@bb0155]\] which leads to an unbalanced healthy homeostasis in aged people \[[@bb0150],[@bb0160],[@bb0165]\], as well as fastening the aging process \[[@bb0170]\].

The purpose of this study was to investigate the effects of melatonin on the regulation of steroid hormones and cytokine signaling during the development of acute *T. cruzi* infection. These findings have significant functional relevance, since an immunoendocrine imbalance occurs during both aging and Chagas disease. Then, we focused on the quantification of melatonin by Elisa and circulating steroids (corticosterone, 11-dehydrocorticosterone (11-DHC), cortisol, cortisone, aldosterone and progesterone) at tissue and systemic level by using a high-resolution multiple reaction monitoring (MRM^HR^) - based mass spectrometry approach. The cytokine repertoire, including IL-1α and IL-1β, IL-6 and TGF-β were also evaluated during the development of acute *T. cruzi* infection.

2. Material and methods {#s0010}
=======================

2.1. Reagents {#s0015}
-------------

The molecular standards cortisol, cortisone, corticosterone, progesterone, aldosterone, cortisone-d8, corticosterone-d4 and formic acid were purchased from Sigma-Aldrich (St. Louis, MO, USA). 11-Dehydrocorticosterone (11-DHC) from Steraloids Inc. (Newport, RI, USA). Methanol (MeOH), acetonitrile (ACN), both HPLC grade, and Milli-Q water system were available from Merck (Kenilworth, NJ, USA). For solid-phase extraction, a Waters Extraction Manifold (Milford, MA, USA) was used, and HyperSep C18 cartridges (500 mg sorbent, 2.8 mL) provided by Thermo Fisher Scientific (Bellefonte, PA, USA). RPMI 1640 medium, anti-corticosterone antibody and trypan staining were purchased from Sigma (Sigma-Aldrich, St Louis, MO, USA). The commercial enzyme-linked immunosorbent assay (ELISA) kit for IL-1β (Catalog \#RLB00), IL-6 (Catalog \# R6000B) were obtained from R&D Systems (Minneapolis, MN, USA). TGF-β (Catalog \# MB100B) levels were analyzed using a commercial ELISA Kit (BioLegend, San Diego, CA, USA). Melatonin (Catalog \# RE54021) levels were analyzed using a commercial ELISA Kit (IBL, Hamburg, Germany). Fetal bovine serum (FBS) was purchased from Gibco (GIBCO-Life Technologies, Baltimore, MD, USA).

2.2. Animals {#s0020}
------------

All animal assays were designed only after due approbation of the Ethics Committee (number: 15.1.886.609) on Animal Use of the University of São Paulo, *Campus* of Ribeirão Preto, complying with the guiding principles of the National Council for the Control of Animal Experimentation (CONCEA-Brazil). Male *Wistar* rats, 5 weeks (n = 20) to 18 months (n = 20) old, weighing between 100--150 g and 500--600 g respectively, were kept in an accredited animal facility at the College of Pharmaceutical Sciences of Ribeirão Preto (FCFRP). Animals were placed in a regulated environment temperature, between 22 and 24 °C and maintained on a 12 h light-dark cycle, with *ad libitum* access to commercial rodent diet and water.

2.3. Experimental infection, treatment and euthanasia {#s0025}
-----------------------------------------------------

Male *Wistar* rats were infected with the Y strain of *T. cruzi* (1 × 10^5^ blood trypomastigotes/animal, intraperitoneally). Melatonin treatment (5 mg/kg/day; orally; suspended in 0.1 mL of polyethylene glycol 400 solution) started concomitantly with parasite infection and it was daily maintained until the day of the experiments (9 days post-infection (dpi). Animals were randomly divided into eight groups: young control (no melatonin treated - YC), young melatonin treated (YMC), young *T. cruzi* infected (YI), young *T. cruzi* infected melatonin treated (YMI), middle-aged control (MC), middle-aged melatonin treated (MMC), middle-aged *T. cruzi* infected, (MI) and middle-aged *T. cruzi* infected melatonin treated (MMI). After a short time animals were humanely anaesthetized with tribromoethanol 2.5% by administration of 0.1 mL/10 g of body weight and decapitated (at 9th dpi) for blood, serum and tissue collection for the performance of experimental protocols.

2.4. Tandem mass spectrometry (LC-MS/MS) {#s0030}
----------------------------------------

Corticosterone and 11DHC from plasma and adrenal were quantified by mass spectrometry (MS) as previously described (Peti et al., 2018). Tissues were homogenized (Mixer Homogenizer, Labortechnik, Wasserburg, Bavaria, Germany) in methanol:water (1:1 v/v), centrifuged, and the supernatant was recovered. Supernatants and plasma were purified as previously described (Galvão et al., 2016). Samples were analyzed using the mass spectrometer TripleTOF 5600^+^(Sciex, Foster, CA, USA) coupled with the liquid chromatography system Nexera (Shimadzu Corp., Kyoto, Japan). Data were processed using PeakView and MultiQuant software.

2.5. Cytokine assays and melatonin levels {#s0035}
-----------------------------------------

Serum samples were used for the detection IL-1β, IL-6, TGF-β and melatonin levels using two-site sandwich ELISA with monoclonal antibody. Standard curves were used for evaluating cytokine concentrations (pg/mL) read at 450 nm and quantified by using an automated microplate ELISA reader (BIOTEK SYNERGY H1M). MILLIPLEX assay kit (Cat. \# RECYTMAG-65K Millipore) and MAGPIX Multiplexing System (MilliporeSigma) was used for the detection of IL-1α.

2.6. Statistical analysis {#s0040}
-------------------------

Graph Pad Prism version 5.0 was used to analyze all data (GraphPad Software, Inc., San Diego, CA, USA; one-way ANOVA with Bonferroni\'s post test) based on variance difference significance among groups. Significance was assured for p \< 0.05 (mean ± standard error of the mean (SEM).

3. Results {#s0045}
==========

Studies in rats have demonstrated that during *T. cruzi* infection proinflammatory mediators such as IL-1α and IL-6 trigger the stimulation of the HPA axis \[[@bb0030]\]. Only one paper describe the relationship of melatonin and steroidal hormones \[[@bb0175]\], and for experimental Chagas disease nothing is known concerning to the role of this indoleamine upon the systemic and tissue levels of steroidal hormones such as 11-DHC, cortisol, cortisone, aldosterone and progesterone.

The MRM^HR^ method is one of accurate method of analysis through liquid chromatographic tandem mass spectrometry for evaluation of low-concentration metabolites in biological samples. This method was applied in the adrenal tissue and plasma samples of rats and allows the quantification of lower steroid hormones concentrations simultaneously with precision and accuracy.

To get some insight into the ability of melatonin to modulate the hormonal response of *T. cruzi* infected rats, we evaluated the production of corticosterone ([Fig. 1](#f0005){ref-type="fig"} ), 11-DHC ([Fig. 2](#f0010){ref-type="fig"} ), cortisone ([Fig. 3](#f0015){ref-type="fig"} ), cortisol ([Fig. 4](#f0020){ref-type="fig"} ) and aldosterone ([Fig. 5](#f0025){ref-type="fig"} ) and progesterone ([Fig. 6](#f0030){ref-type="fig"} ) in young and middle-aged animals. Treatment with melatonin reduced the basal levels of these hormones in all middle-aged melatonin treated rats, infected or not, as compared to their untreated groups. However, the plasma levels of corticosterone ([Fig. 1](#f0005){ref-type="fig"}D), 11-DHC ([Fig. 2](#f0010){ref-type="fig"}D), cortisone ([Fig. 3](#f0015){ref-type="fig"}D), cortisol ([Fig. 4](#f0020){ref-type="fig"}D) did not significantly decline among all infected melatonin-treated animals. On the other hand, reduced concentrations of progesterone were induced by melatonin, for juvenile and infected subjects ([Fig. 6](#f0030){ref-type="fig"}D).Fig. 1Corticosterone quantification in adrenal tissue (ng/adrenal gland) and plasma (ng/mL) samples evaluated by MRM^HR^ method through liquid chromatographic tandem mass spectrometry (HPLC-MS/MS), from young and middle-aged *Wistar* rats, on the 9th day post-infection of experimental *T. cruzi* infection, for the following groups: young control (YC), young melatonin control (YMC), young infected (YI), young melatonin infected (YMI), middle-aged control (MC), middle-aged melatonin control (MMC), middle-aged infected (MI) and middle-aged melatonin infected (MMI). (A-B)- Adrenal tissue, (C-D)-Plasma samples, (E)-representative chromatogram retention time and CAD spectra for corticosterone. Results are shown as the means ± SEM of n = 5 to 6 rats. One-way ANOVA followed by Bonferroni\'s multiple comparison test were used to compare groups (*\*P* *\<* *0.05*).Fig. 1Fig. 211-DHC quantification in adrenal tissue (ng/adrenal gland) and plasma (ng/mL) samples evaluated by MRM^HR^ method through liquid chromatographic tandem mass spectrometry (HPLC-MS/MS), from young and middle-aged *Wistar* rats, on the 9th day post-infection of experimental *T. cruzi* infection, for the following groups: young control (YC), young melatonin control (YMC), young infected (YI), young melatonin infected (YMI), middle-aged control (MC), middle-aged melatonin control (MMC), middle-aged infected (MI) and middle-aged melatonin infected (MMI). (A-B)- Adrenal tissue, (C-D)-Plasma samples, (E)-representative chromatogram retention time and CAD spectra for 11-DHC. Results are shown as the means ± SEM of n = 5 to 6 rats. One-way ANOVA followed by Bonferroni\'s multiple comparison test were used to compare groups (*\*P* *\<* *0.05*).Fig. 2Fig. 3Cortisone quantification in adrenal tissue (ng/adrenal gland) and plasma (ng/mL) samples evaluated by MRM^HR^ method through liquid chromatographic tandem mass spectrometry (HPLC-MS/MS), from young and middle-aged *Wistar* rats, on the 9th day post-infection of experimental *T. cruzi* infection, for the following groups: young control (YC), young melatonin control (YMC), young infected (YI), young melatonin infected (YMI), middle-aged control (MC), middle-aged melatonin control (MMC), middle-aged infected (MI) and middle-aged melatonin infected (MMI). (A-B)- Adrenal tissue, (C-D)-Plasma samples, (E)-representative chromatogram retention time and CAD spectra for cortisone. Results are shown as the means ± SEM of n = 5 to 6 rats. One-way ANOVA followed by Bonferroni\'s multiple comparison test were used to compare groups (*\*P* *\<* *0.05*).Fig. 3Fig. 4Cortisol quantification in adrenal tissue (ng/adrenal gland) and plasma (ng/mL) samples evaluated by MRM^HR^ method through liquid chromatographic tandem mass spectrometry (HPLC-MS/MS), from young and middle-aged *Wistar* rats, on the 9th day post-infection of experimental *T. cruzi* infection, for the following groups: young control (YC), young melatonin control (YMC), young infected (YI), young melatonin infected (YMI), middle-aged control (MC), middle-aged melatonin control (MMC), middle-aged infected (MI) and middle-aged melatonin infected (MMI). (A-B)- Adrenal tissue, (C-D)-Plasma samples, (E)-representative chromatogram retention time and CAD spectra for cortisol. Results are shown as the means ± SEM of n = 5 to 6 rats. One-way ANOVA followed by Bonferroni\'s multiple comparison test were used to compare groups (*\*P* *\<* *0.05*).Fig. 4Fig. 5Aldosterone quantification in adrenal tissue (ng/adrenal gland) and plasma (ng/mL) samples evaluated by MRM^HR^ method through liquid chromatographic tandem mass spectrometry (HPLC-MS/MS), from young and middle-aged *Wistar* rats, on the 9th day post-infection of experimental *T. cruzi* infection, for the following groups: young control (YC), young melatonin control (YMC), young infected (YI), young melatonin infected (YMI), middle-aged control (MC), middle-aged melatonin control (MMC), middle-aged infected (MI) and middle-aged melatonin infected (MMI). (A-B)- Adrenal tissue, (C-D)-Plasma samples, (E)-representative chromatogram retention time and CAD spectra for aldosterone. Results are shown as the means ± SEM of n = 5 to 6 rats. One-way ANOVA followed by Bonferroni\'s multiple comparison test were used to compare groups (*\*P* *\<* *0.05*).Fig. 5Fig. 6Progesterone quantification in adrenal tissue (ng/adrenal gland) and plasma (ng/mL) samples evaluated by MRM^HR^ method through liquid chromatographic tandem mass spectrometry (HPLC-MS/MS), from young and middle-aged *Wistar* rats, on the 9th day post-infection of experimental *T. cruzi* infection, for the following groups: young control (YC), young melatonin control (YMC), young infected (YI), young melatonin infected (YMI), middle-aged control (MC), middle-aged melatonin control (MMC), middle-aged infected (MI) and middle-aged melatonin infected (MMI). (A-B)- Adrenal tissue, (C-D)-Plasma samples, (E)-representative chromatogram retention time and CAD spectra for progesterone. Results are shown as the means ± SEM of n = 5 to 6 rats. One-way ANOVA followed by Bonferroni\'s multiple comparison test were used to compare groups (*\*P* *\<* *0.05*).Fig. 6

Our results confirm that the aging affects the steroidal hormone profile, since an increased production of corticosterone ([Fig. 1](#f0005){ref-type="fig"}A), 11-DHC ([Fig. 2](#f0010){ref-type="fig"}C), cortisone ([Fig. 3](#f0015){ref-type="fig"}A), cortisol ([Fig. 4](#f0020){ref-type="fig"}A), aldosterone ([Fig. 5](#f0025){ref-type="fig"}A) and progesterone ([Fig. 6](#f0030){ref-type="fig"}C) was observed in middle-aged control animals as compared to young ones. Corticosterone ([Fig. 1](#f0005){ref-type="fig"}C), 11-DHC ([Fig. 2](#f0010){ref-type="fig"}C), cortisone ([Fig. 3](#f0015){ref-type="fig"}C) and cortisol ([Fig. 4](#f0020){ref-type="fig"}C) concentrations were significantly lower in plasma from uninfected middle-aged melatonin treated animals. *T. cruzi* infection down-regulated the adrenal production of cortisone ([Fig. 3](#f0015){ref-type="fig"}A--B), cortisol ([Fig. 4](#f0020){ref-type="fig"}A--B) and aldosterone ([Fig. 5](#f0025){ref-type="fig"}A--B) in middle-aged infected rats, as compared to their respective uninfected counterparts.

The next step, the pro-inflammatory cytokines involved in the HPA regulation: IL-1α, IL-1β, IL-6 and TGF- β were evaluated. A significant increase in IL-1α ([Fig. 7](#f0035){ref-type="fig"}A and B) concentrations was observed for infected middle-aged and young rats, when compared with the control ones. As expected, the immunosenescence process was linked to elevated levels of IL-1 β ([Fig. 7](#f0035){ref-type="fig"}C and D) and IL-6 ([Fig. 8](#f0040){ref-type="fig"}A and B) as found for all middle-aged rats as compared to juvenile ones. We further examine if melatonin\'s actions were related with alterations in the kinetics of cytokine output during the early *T. cruzi* infection. Our results demonstrated reduced IL-1α and IL-1β production, a key cytokine that has been entangled with chagasic cardiac hypertrophy, for middle-aged infected melatonin supplemented rats ([Fig. 7](#f0035){ref-type="fig"}B and D). Melatonin treated middle-aged rats displayed lower levels of IL-6, excepting the young ones ([Fig. 8](#f0040){ref-type="fig"}A and B). Reduced concentrations of TGF-β were triggered for young infected rats when compared to the untreated ones ([Fig. 8](#f0040){ref-type="fig"}D). Melatonin treated middle-aged control groups displayed reduced concentrations of TGF-β ([Fig. 8](#f0040){ref-type="fig"}C).Fig. 7IL-1α levels (pg/mL), were measured by MILLIPLEX assay (A-B) and IL-1β levels (pg/mL), measured by ELISA (C-D), after melatonin treatment, from young and middle-aged *Wistar* rats, on the 9th day post-infection of experimental *T. cruzi* infection, for the following groups: young control (YC), young melatonin control (YMC), young infected (YI), young melatonin infected (YMI), middle-aged control (MC), middle-aged melatonin control (MMC), middle-aged infected (MI) and middle-aged melatonin infected (MMI). (A) Control groups and (B) Infected groups. Results are shown as the means ± SEM of n = 5 to 6 rats. One-way ANOVA followed by Bonferroni\'s multiple comparison test was used to compare groups (\**P \< 0.05*).Fig. 7Fig. 8IL-6 levels (A-B) and TGF-β (C-D) (pg/mL) were measured by ELISA, after melatonin treatment, from young and middle-aged *Wistar* rats, on the 9th day post-infection of experimental *T. cruzi* infection, for the following groups: young control (YC), young melatonin control (YMC), young infected (YI), young melatonin infected (YMI), middle-aged control (MC), middle-aged melatonin control (MMC), middle-aged infected (MI) and middle-aged melatonin infected (MMI). (A) Control groups and (B) Infected groups. Results are shown as the means ± SEM of n = 5 to 6 rats. One-way ANOVA followed by Bonferroni\'s multiple comparison test was used to compare groups (*\*P* *\<* *0.05 and \*\*P* *\<* *0.01*).Fig. 8

Since, an important decay in endogenous melatonin synthesis occurs with aging, systemic levels of this hormone were quantified in young and middle-aged groups. Serum melatonin levels were reduced with age and predominantly higher in young and middle-aged infected rats compared to control animals ([Fig. 9](#f0045){ref-type="fig"} ). Melatonin levels were significantly higher in all middle-aged rats (control or infected) supplemented with melatonin, as compared to untreated ones.Fig. 9Melatonin (pg/mL) levels were measured by ELISA, after melatonin treatment, from young and middle-aged *Wistar* rats, on the 9th day post-infection of experimental *T. cruzi* infection, for the following groups: young control (YC), young melatonin control (YMC), young infected (YI), young melatonin infected (YMI), middle-aged control (MC), middle-aged melatonin control (MMC), middle-aged infected (MI) and middle-aged melatonin infected (MMI). Results are shown as the means ± SEM of n = 5 to 6 rats. One-way ANOVA followed by Bonferroni\'s multiple comparison test was used to compare groups (\**P \< 0.05*).Fig. 9

The anti-apoptotic abilities of melatonin were evidenced in our study. Early and late thymocyte apoptosis from all middle-aged melatonin-treated animals were statistically reduced as compared to non-supplemented ones respectively ([Fig. 10](#f0050){ref-type="fig"}A and B). However, as shown in [Fig. 10](#f0050){ref-type="fig"}, the percentages of early (A) and late thymocyte apoptosis (B) did not significantly decline among all young melatonin-treated animals. Significantly higher proportions of both early (A) and late apoptotic thymocytes (B) were displayed for all middle-aged animals, as compared to young counterparts ([Fig. 9](#f0045){ref-type="fig"}) triggered by the aging process.Fig. 10Thymocyte apoptosis was measured by double staining with FITC-labeled annexin V and PI in young and middle-aged *Wistar* rats, on the 9th day post-infection of experimental *T. cruzi* infection, for the following groups: young control (YC), young melatonin control (YMC), young infected (YI), young melatonin infected (YMI), middle-aged control (MC), middle-aged melatonin control (MMC), middle-aged infected (MI) and middle-aged melatonin infected (MMI). Data are expressed as: (A) percentages (%) of early apoptotic cells (annexin V+/PI−), (B) late apoptotic cells (annexin V+/PI+) (%), (C) cell viability of thymocytes (%). Results are shown as the means ± SEM of n = 5 to 6 rats. One-way ANOVA followed by Bonferroni\'s multiple comparison test was used to compare groups (*\*P \< 0.05*)*.*Fig. 10

The percentage of viable thymocytes in all young and middle-aged melatonin treated infected rats, was statistically enhanced when compared to untreated counterparts ([Fig. 10](#f0050){ref-type="fig"}C). Oppositely, a significant drop in the proportion of viable thymocytes in middle-aged control animals was observed as compared to young groups ([Fig. 10](#f0050){ref-type="fig"}).

4. Discussion {#s0050}
=============

A bulk of evidence has shown that altered steroidal hormone production might be related to a number of stress-induced disorders such as major depression, stress/trauma, hypertension, immune suppression and septic shock \[[@bb0180], [@bb0185], [@bb0190]\]. Although the exact underlying complex mechanisms of the Chagas disease pathology are still unveiled, the coexistence of endocrine and immunological disturbances occurs during the early *T. cruzi* infection although the mechanisms are not well established \[[@bb0015],[@bb0195]\]. Then, herein our aim was the quantification of the steroidal hormones in a sensitive and specific way, using the MRMHR method, and explores the impact of melatonin supplementation on cytokine production and steroidal hormones fractions during the early *T. cruzi* infection.

Aging process is associated with functional changes in the nervous, endocrine and immune systems \[[@bb0200]\]. Mitochondrial dysfunction also appears to contribute to progression of the aging process leading to defects in the steroidogenesis. As we age, morphological and functional changes of the adrenal gland occur leading to alterations in hormonal output and decline in adrenal androgen synthesis, although increased expression and activity of enzymes related to glucocorticoid synthesis occurs, promoting an immunoendocrine imbalance, with adrenal hypertrophy and cortisol hypersecretion \[[@bb0205]\] While the adrenal cortisol concentration increases with the aging process, a reduced melatonin release by pineal gland is evident, being cortisol considered by some authors as an antagonist mediator for pineal melatonin release. In line with this, our data show that serum melatonin levels were reduced in middle aged animals as compared to young ones.

Since in rodents stress responses are controlled by corticosterone production. Some researchers have described enhanced plasmatic cortisol concentrations and hypertrofic adrenal glands in mice, after a stress episode. Other papers have considered cortisol as a key for stress activation in both mice \[[@bb0210]\] and rats \[[@bb0215]\]. Furthermore, cortisol displays enhanced glucocorticoid potency when compared to corticosterone \[[@bb0220]\].

Interestingly, independent corticosterone secretion was observed in rat testis out of the HPA axis bustle from progesterone \[[@bb0225]\]. This helps to explain how the higher age-related corticosterone concentrations, may be due to the elevated availability of progesterone, which can be correlated with the individual concentrations of progesterone and corticosterone. Lymphoid organs are able to produce locally corticosterone through the action of the inactive metabolite, from 11-DHC to 11β-HSD1, being this last compound normally elevated in aged animals \[[@bb0230]\]. Furthermore, physiological investigations have also shown aldosterone autonomous secretion in age-related subjects leading to enhanced risk of developing cardiovascular diseases \[[@bb0235]\]. Interestingly, this pattern of steroidal composition during the aging process parallels our findings. We found that the adrenal production of corticosterone, cortisone, cortisol and aldosterone were markedly increased in middle-aged control animals as compared to young ones. Furthermore, increased plasma concentrations of 11-DHC and progesterone were induced by aging process, as observed for middle-aged rats as compare to young counterparts.

An increase in the secretion of corticosterone induced by *T. cruzi* drive a systemic inflammation which is closely correlated with hypertrophic adrenal glands, specially the fasciculate zone, and thymic alterations in infected animals \[[@bb0240]\]. Yet, Villar et al. have reported that patients with cardiac forms of chronic Chagas disease have higher adrenal expression of several steroidogenic enzymes, including cytochrome P450, family 11, subfamily A, polypeptide 1 (CYP11A1), CYP11B1, 11β-hydroxysteroid dehydrogenase type 1 (HSD1), and steroidogenic acute regulatory protein \[[@bb0240]\]. Chumbinho et al. (2012) also described that the mortality rate in *T. cruzi* infected mice was under the direct influence of aldosterone. According to the same authors, aldosterone blockage with spironolactone (an aldosterone antagonist) attenuates the parasite load and reduces the severity of Chagas cardiomyopathy \[[@bb2005]\]. Currently is also known that a prolonged aldosterone treatment (between 4 and 5 weeks) triggers enhanced oxidative stress production and accounts for a proinflammatory phenotype. Although the exact role of melatonin on aldosterone production has remained controversial, we found that melatonin treatment decreased the adrenal aldosterone production in all treated rats. Our findings demonstrate that the adrenal steroid production (cortisone, cortisol and aldosterone) in middle-aged and infected rats was worsened with a significant reduction of these adrenal hormones as compared to their respective uninfected counterparts. Interestingly, *T. cruzi* infection *per si* triggered significant increased systemic levels of melatonin in both young and middle-aged infected animals as compared to uninfected ones. In infected animals the immune system orchestrates a cellular and humoral response and all these cells display receptors for this indoleamine, being able to produce this hormone. Then, we propose that melatonin enhanced levels has a wide range of inducers, such as seasonal period, immune response, infection and animal species.

An adequate melatonin supplementation, even if started on late life, has been investigated for their potential to reversibly counteract the age-related impairment of thymopoiesis and immune dysfunctions in old animals \[[@bb0245]\]. Cortisol secretion is inhibited by melatonin\'s action \[[@bb0250]\], indicating that there is an upside down relationship between circadian cortisol and melatonin cycles \[[@bb0255]\]. Yet, these inhibitory effects were reversed when cells were co-treated with the MT1/MT2 antagonist luzindole, suggesting the presence of functional melatonin receptors in the adrenal cortex \[[@bb0250]\]. However, nothing is known about endogenous 11-DHC levels and melatonin treatment. Our findings demonstrated that the exogenous administration of melatonin exerts an inhibitory effect on the adrenal secretion of corticosterone, 11-DHC, cortisone and cortisol in elderly *T. cruzi* infected rats. Longer melatonin schedules in *T. cruzi*-infected rats trigger enhanced serum concentrations of this indoleamine, specially in middle-aged groups.

It is well explained that the exposure to glucocorticoids and hydroxyl radical induce thymocyte apoptosis, and melatonin treatment reverts this process \[[@bb0260],[@bb0265]\]. Sainz et al. described that melatonin treatment triggered a reduction in pro-apoptotic markers in the cortex of the murine thymus \[[@bb0270]\]. A plethora of *in vivo* and *in vitro* experiments conclusively demonstrate that melatonin can protect primary lymphoid organs against apoptosis through a mechanism that is dependent of its anti-apoptotic properties \[[@bb0265]\] and its ability to modulate cell proliferation \[[@bb0245]\]. Another potential theory to explain melatonin\'s antiapoptotic effects is its role in the down regulation on the glucocorticoid receptor in thymocytes \[[@bb0260]\] as well as the antioxidant properties of this indoleamine. Our experiments support the previously reported, since we found that early and late apoptotic thymocytes were reduced in *T. cruzi* middle-aged melatonin supplemented groups.

Glucocorticoids have been reported as the central mediators of thymocyte apoptosis during *T. cruzi* infection, worsening thymocyte depletion probably due to enhanced glucocorticoid levels \[[@bb0015],[@bb0030]\]. Furthermore, some papers describe that the age-related deregulation in pinealocytes and thymocytes is linked with enhanced mortality percentages triggered by distinct pathologies such as infectious diseases, cancer, and autoimmunity, as well as reduced vaccine response in the elderly \[[@bb0025],[@bb0280], [@bb0285], [@bb0290]\]. Over a lifetime, increased apoptosis in various cell types occurs. For animal models, thymocyte apoptosis has also been described for older mice \[[@bb0295],[@bb0300]\] and the most significant changes are found in the thymic cortex \[[@bb0305]\]. In line with this, for all middle-aged animals, we found higher proportions of both early and late apoptotic thymocytes, as compared to young counterparts. Furthermore, reduced rates of thymocyte viability for infected animals and for middle-aged control groups was evidenced.

Overproduction of systemic cytokines and pro-inflammatory markers, such as IL-1β and IL-6 \[[@bb0310], [@bb0315], [@bb0320], [@bb0325]\] are a common phenomenon during the aged-related changes and may be linked to metabolic and pathophysiological changes that occur during different acute inflammatory diseases \[[@bb0330]\]. Upon mitochondrial dysfunction, several pro-inflammatory cytokines such as IL-1, IL-6, and TNF-α are produced by endothelial cells, consequently up-regulating intercellular adhesion molecule-1 (ICAM-1) expression which attracts monocyte activation and adhesion \[[@bb0335]\] For a well orchestrated stress response, mitochondria play an essential role to provide energy being totally integrated to the HPA axis. Studies carried out in the naturally found old male senescence-accelerated murine model have confirmed elevated IL-1β, IL-6 and TNF-α levels in aged animals. Additionally, a hyper response of the HPA axis, through the activity of a wide range of immune cell mediators, including IL-1β and IL-6 is also observed during acute Chagas\' disease \[[@bb0340]\]. A close connection between *T. brucei* infection in humans and the higher production of IL-6 has been already described \[[@bb0345],[@bb0350]\]. Enhanced IL-6 gene expression has been observed after *in vitro T. cruzi* infection of ACTH-producing cells \[[@bb0355]\].

Notably, experimental assays have found a relationship between IL-6 and the induction of heighten concentrations of glucocorticoid and ACTH \[[@bb0360],[@bb0365]\]. Dinkel et al. (2003) reported that chronically higher glucocorticoid concentrations in rats are correlated with increased IL-1β and TNF-α mRNA expressions. Interestingly, it has been postulated that the higher expression of nuclear factor-κB (NF-κB), mitogen-activated kinase (MAPK) as well as pro-inflammatory cytokines could be a consequence of the enhanced corticosterone concentrations, which lead to sustain the inflammatory state \[[@bb0370]\]. Another study demonstrates that chronic chagasic patients have a series of important metabolic and hormonal abnormalities directly correlated with the increased IL-6 concentrations \[[@bb0375]\]. In line with these earlier studies, we also demonstrated the regulatory properties of IL-1β and IL-6 during aging and *T. cruzi* infection where a significant increased serum levels of these cytokines were found in middle-aged rats.

Melatonin has a protective ability, inhibiting long-term changes in inflammatory responses at different levels \[[@bb0380]\], thereby reducing the production of several pro-inflammatory immune mediators, including leukotrienes, prostanoids, cytokines and adhesion molecules. Furthermore, after melatonin administration in old mice, reduced concentrations of the Th-1 cytokines profile and elevated IL-10 concentrations were found \[[@bb0385],[@bb0390]\]. Attaining similar kind of response in a rat model of heart stroke submitted to melatonin therapy, it was demonstrated that melatonin triggered a reduced inflammation reaction besides protecting against multi-organ injury as a result from severe heat exposure \[[@bb0395]\]. Peng et al. have evidenced that after melatonin administration, an important reduction in the output of inflammatory cells, neutrophils and IL-1β in the bronchoalveolar lymphoid tissue occur \[[@bb0400]\]. Furthermore, Shin et al. demonstrated that in lung tissue exposed to lipopolysaccharide, melatonin treatment downregulated the expression of TGF-β1 \[[@bb0405]\]. Our findings constitute the first report of reduced serum IL-1β and IL-6 levels in middle-aged *T. cruzi* infected rats under melatonin therapy. Melatonin also exerts a negative influence on TGF-β production, with reduced levels for young infected and middle-aged control rats.

In summary, for the first time our compelling data clearly showed the age-related changes in adrenal and plasma steroidal hormones profiling as well cytokine production in *Wistar* rats confirming the efficiency of melatonin intervention in the regulation and signaling hormonal pathways and inflammatory mediators.
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